Literature DB >> 7524206

Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAE hybrid, on complement-mediated swine endothelial cell lysis.

S Miyagawa1, R Shirakura, K Iwata, S Nakata, G Matsumiya, H Izutani, H Matsuda, A Terado, M Matsumoto, S Nagasawa.   

Abstract

We established several swine endothelial cell (SEC) lines, expressing human MCP (CD46), DAF (CD55), and MCP/DAF hybrid by transfection of cDNA, and assessed the function of these transfectant molecules on complement-mediated cell lysis as an in vitro hyperacute rejection model of swine to human discordant xenograft. Discordant organ xenografts are hyperacutely rejected by complement activation. Amelioration of complement-mediated lysis by these transfectant molecules was tested in each SEC line by lactate dehydrogenase assay. Naive swine endothelial cells were markedly damaged by human complement mainly via the classical pathway, activating only minimally the alternative pathway of human complement. Both MCP and DAF protected SEC from human complement attack in parallel with the expression density, with DAF being more effective than MCP. The MCP/DAF hybrid was more effective than MCP alone, and as effective as DAF in this system. The results suggest that the transfection of DAF or the MCP/DAF hybrid cDNA into organs to be transplanted could protect against hyperacute rejection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524206

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  The possible use of HLA-G1 and G3 in the inhibition of NK cell-mediated swine endothelial cell lysis.

Authors:  K Matsunami; S Miyagawa; R Nakai; A Murase; R Shirakura
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

2.  Trial using pig cells with the H-D antigen knocked down.

Authors:  Aki Yamamoto; Kosuke Ikeda; Dandan Wang; Shino Nakatsu; Yuichi Takama; Takehisa Ueno; Hiroshi Nagashima; Akihiro Kondo; Masahiro Fukuzawa; Shuji Miyagawa
Journal:  Surg Today       Date:  2012-08-05       Impact factor: 2.549

3.  Molecular remodelling of human CD46 for xenotransplantation: designing a potent complement regulator without measles virus receptor activity.

Authors:  N A Begum; Y Murakami; S Mikata; M Matsumoto; M Hatanaka; S Nagasawa; T Kinoshita; T Seya
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

4.  BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death.

Authors:  S Shimizu; A Konishi; T Kodama; Y Tsujimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 5.  Perspectives on the Optimal Genetically Engineered Pig in 2018 for Initial Clinical Trials of Kidney or Heart Xenotransplantation.

Authors:  David K C Cooper; Mohamed Ezzelarab; Hayato Iwase; Hidetaka Hara
Journal:  Transplantation       Date:  2018-12       Impact factor: 4.939

6.  Generation of a felinized swine endothelial cell line by expression of feline decay-accelerating factor.

Authors:  Luna Izuhara; Norifumi Tatsumi; Shuji Miyagawa; Satomi Iwai; Masahito Watanabe; Shuichiro Yamanaka; Yuichi Katsuoka; Hiroshi Nagashima; Hirotaka J Okano; Takashi Yokoo
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

7.  The Regulation of Neutrophil Extracellular Trap-induced Tissue Damage by Human CD177.

Authors:  Tomohisa Yoneyama; Akira Maeda; Shuhei Kogata; Chiyoshi Toyama; Pei-Chi Lo; Kazunori Masahata; Masafumi Kamiyama; Tomoko Haneda; Chizu Okamatu; Hiroshi Eguchi; Yuko Tazuke; Takehisa Ueno; Hiroomi Okuyama; Shuji Miyagawa
Journal:  Transplant Direct       Date:  2021-07-23

Review 8.  Aspects of the Complement System in New Era of Xenotransplantation.

Authors:  Shuji Miyagawa; Akira Maeda; Chiyoshi Toyama; Shuhei Kogata; Chizu Okamatsu; Riho Yamamoto; Kazunori Masahata; Masafumi Kamiyama; Hiroshi Eguchi; Masahito Watanabe; Hiroshi Nagashima; Masahito Ikawa; Katsuyoshi Matsunami; Hiroomi Okuyama
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.